Savient Pharmaceuticals SVNT
-
New Morningstar Analyst Report for Savient Pharmaceuticals
Despite numerous setbacks and poor execution, Savient still has a strong product.
-
4 Highly Liquid Biotech Stocks With Bullish Short Trends
By Kapitall : Liquidity is a very important consideration for biotech stocks. Because many biotech firms do not generate earnings until after launching a successful drug, many have to rely on their sources of liquidity to continue operations. To illustrate, we ran a screen on the biotech industry
-
Savient's loss widens, shares fall
(Reuters) - Savient Pharmaceuticals Inc posted a wider-than-expected loss on weak sales of its gout drug Krystexxa in the first two months, sending its shares down 13 percent.
-
UPDATE 2-Savient's loss widens, shares fall
May 9 (Reuters) - Savient Pharmaceuticals Inc posted a wider-than-expected loss on weak sales of its gout drug Krystexxa in the first two months, sending its shares down 13 percent.
-
Krystexxa 1Q Sales Disappoint; We Plan to Lower Our Fair Value Estimate for Savient
Savient SVNT reported weaker-than-expected first-quarter Krystexxa sales, and we plan to lower our fair value estimate to $1.50 from …
-
Savient Pharmaceuticals ( SVNT ): Q1 EPS of -$0.49 in-line. Revenue of $3.5M (+169% Y/Y) misses by $1.1M. (PR)
Savient Pharmaceuticals ( SVNT ): Q1 EPS of -$0.49 in-line. Revenue of $3.5M (+169% Y/Y) misses by $1.1M . ( PR ) Post your comment!
-
Savient Pharmaceuticals ([[ SVNT ]] +18%) gets a pop after entering into secured arrangements with some of its creditors to restructure its debt load and head off recent criticisms of its financial ...
Savient Pharmaceuticals ( SVNT +18% ) gets a pop after entering into secured arrangements with some of its creditors to restructure its debt load and head off …
-
UPDATE 1-Savient says court denies creditor's injunction request
May 8 (Reuters) - Savient Pharmaceuticals Inc said a Delaware court denied a request for an injunction by its largest creditor, Tang Capital Partners, to halt Savient's plan to raise about $44...
-
Biotechnology And Drugs Stocks To Watch Next Week
By StockPandit : Next week is a busy earnings season, with many quarterly earnings releases scheduled and a bunch of stocks to watch. However, my focus is on biotechnology and drugs stocks that have earnings due in the next week. This article provides earnings previews on several stocks to consider
-
Placing Savient Under Review
On Tuesday, Savient SVNT filed an 8-K disclosing that it has been served with a creditor derivative action complaint by Tang Capital Partners. We are placing our fair value estimate under review as we analyze the merits and potential implications of Tang Capital's claims.